Vaccine
Safety > Research
Epidemiologic Methods in Immunization Programs
As printed in Epidemiologic Reviews, 1996, Volume 18 (No. 2), page 99-117.
Authors: |
Robert T. Chen, M.D., M.A.
Walter A. Orenstein, M.D.
National Immunization Program
Centers for Disease Control and Prevention
Atlanta, Georgia 30333
|
Introduction
Immunizations are among the most successful and cost-effective disease
prevention interventions available.1 In the United States, the introduction of
routine immunizations has greatly reduced the incidence of several vaccine-preventable
diseases (Table 1). Similar success in disease reduction has been demonstrated by
immunization programs in many other countries.2,3 The World Health
Organization's Expanded Programme on Immunizations (EPI), with assistance from United
Nation's Children's Fund (UNICEF) and other donors, has made great strides in extending
these benefits to developing countries.4 Immunizations permitted the global
eradication of smallpox5 and may do the same for poliomyelitis6 and
some other diseases. Interest in immunization programs continues to grow as countries
attempt to improve the rational allocation of their scarce health resources. Developments
in biotechnology and immunology offer the promise of new vaccines against many diseases
old and new, ranging from malaria to Acquired Immunodeficiency Syndrome (AIDS)7,
including some non-infectious diseases like cancer.8 In sum, immunization
programs represent an impressive attempt by the human species, via science and social
organization, to purposefully alter the ecology of certain infectious diseases in its
favor. While some individuals may view this as hubris against nature9, most
persons willingly accept that less disease is better.
Epidemiologic studies and principles, experimental and observational, play
a critical role in guiding almost all steps of a successful immunization program.10
Prior to licensure, a vaccine must demonstrate its safety and efficacy in phased
clinical trials. Post-licensure, continued close monitoring of the vaccine's safety and
effectiveness is needed, especially early on. But equally important to a vaccine's
ultimate success is the close monitoring of the immunization program itself.
Surveillance for vaccine coverage, disease incidence, and adequacy of the
cold chain provide the benchmarks for an immunization program to judge its progress. Rigor
in design, conduct, and analyses of epidemiologic studies to understand the risk factors
for nonvaccination, vaccine failure, and cold chain failure permits development of
accurate and timely adjustments to immunization programs and policies to ensure their
ultimate success. This review will discuss the epidemiologic methods used in the various
phases of an immunization program drawing largely, though not exclusively, on the
experience in the United States.
Top
of Page
Pre-licensure
Clinical Trials
The goals of the pre-licensure studies are to 1) identify a candidate
vaccine, 2) show that the vaccine is safely tolerated in terms of local and systemic
reactions ("safety"), and 3) demonstrate that the vaccine confers protection
against the target disease ("efficacy"), either directly in terms of disease
reduction, or indirectly, in terms of elicitation of protective antibodies. Pre-licensure
studies are carefully phased in design and conduct. Impressive progress in biotechnology
during recent decades has revolutionalized not only the capability to rapidly identify the
causative organisms for new illnesses11, but also to engineer and produce
vaccines that are potentially safer, more effective, easier to produce, and less costly.12
This biotechnology revolution poses a tremendous challenge to the traditional
"vaccine development system" to provide adequate and timely assessments so that
maximum benefits might be reaped from these advances.7
After isolation and characterization of the causative organism for a
disease, inactivation or attenuation permit the development of candidate vaccines.13
Such candidate vaccine are tested in animals14 before advancing to phased human
clinical trials. Phase I trials usually enroll 10-100 adult volunteers to assess initial
safety tolerance and acceptable vaccine dosage in humans. Phase II trials seek to expand
knowledge about the safety, optimal dose, route of administration, and schedule (primary
series, and if needed, boosters) of the candidate vaccine. Sample sizes usually range from
25-1000 persons.
Phase III clinical trials aim to show that the candidate vaccine is
efficacious in conferring protection on a targeted, at-risk population under controlled
conditions. Safety issues are also examined to the extent the sample size and study
duration permit. As with any clinical trial, issues such as case definition, case finding,
trial design, and sample size must be considered carefully.15
Classically, a prospective, double-blind, randomized, controlled design is used.
Occasionally, studies with open16, historic control17, or household
secondary attack rate18 designs are used.
Based on a comparison of the disease incidence rate of vaccinated to
unvaccinated individuals, the percentage reduction in disease as a result of the
vaccination, or vaccine efficacy, is calculated (see the section on vaccine efficacy and
vaccine effectiveness studies below).19 Comparison of adverse event rates
between the two groups is also made. The accurate ascertainment of cases and, therefore,
the accuracy of the vaccine efficacy calculation, depends greatly on which endpoint is
selected for the trial.
The endpoint "case definition" may be a laboratory result, a
clinical finding, or combination of both. The goal of the immunization may be to prevent
infection [e.g., by Human Immunodeficiency Virus (HIV)], to prevent the final disease
(e.g., AIDS), or prevent severe disease (e.g., pertussis). Whatever the endpoint chosen,
the specificity of the diagnosis is more critical to the accuracy of the vaccine efficacy
estimate than the sensitivity of diagnosis.20 Another key goal of Phase
III trials is to establish a laboratory correlate of human protection if possible. This
permits a potency test to be developed and standardized for use in prerelease testing as
well as a surrogate endpoint in future trials.
Program Goals and Strategies
After a vaccine completes the clinical trials and licensure is imminent,
several decisions must be made prior to its introduction into a vaccine program. The goals
of the program and the appropriate strategies to reach them need to be defined. This is
turn determines how widely the vaccine can be used, which target populations should
receive it, and how rapidly use of the vaccine must be implemented. The disease control
strategy is dictated to a large degree by 1) the epidemiologic features of the disease21,
2) the adequacy of the health infrastructure, and 3) the resources available.22
Vaccination strategies in developing countries may confront difficult choices23,
especially in terms of the balance between a "vertical" (immunization is
directed from the national level as a separate program) vs. an "integrated"
(where it is part of a comprehensive primary care effort) immunization program.24
After considerable experience in disease prevention through vaccination
have been gained, elimination or eradication of the vaccine-preventable disease (the
absence of disease with, and without, a continuing threat of reintroduction, respectively)
is usually considered. Special strategies like "ring immunization" for smallpox25
or "national immunization days" for poliomyelitis26 are usually
required to move from simple disease control to eradication.
Disease surveillance data on age groups, special populations at risk, and
illness complications are important in evaluating the cost and benefits of vaccination
Measles was a disease that affected many young children prior to school entry while
rubella was uncommon before school age.strategies.27,28 For example,
surveillance data were useful in designing strategies for vaccination against measles and
rubella. Thus, measles immunization programs needed to target both children at 1 year of
age and those in elementary school. In contrast, vaccination efforts against rubella could
either be narrowly targeted at prepubertal females29 or be used universally
among all children of both sexes.30 The latter strategy has been shown to
be more successful as vaccine coverage is higher and provides greater herd immunity by
reducing rubella transmission but at a higher cost.31 When adequate
surveillance data are available, different options for control strategies can be modeled
mathematically to obtain quantitative insights in lieu of mere intuition.32
Once a vaccine has shown good results in an efficacy study, an effectiveness
study may be needed to determine if the use of the vaccine in routine public health
practice is indicated. The initial evaluation of the Ty21a oral typhoid vaccine was done
with a liquid formulation that was efficacious but was not suitable for mass production.
Subsequent trials compared more convenient capsule and enteric-coated tablets against the
liquid formulation.33 New health programs today frequently also need to
demonstrate cost-effectiveness, as was done prior to licensure of the Haemophilus
influenzae type b (Hib) polysaccharide34 and varicella35
vaccines.
Phase III trials by necessity must evaluate the efficacy of the candidate
vaccine when used alone. With the increasing number of antigens routinely recommended in
infants and children, simultaneous or combined administration of multiple antigens becomes
increasingly attractive to minimize the costs and the number of health care visits and
injections needed to complete the immunization series.36 The safety and
immunogenicity of simultaneous or combined vaccinations require careful evaluation to
ensure there is no interference in immunogenicity or enhancement of adverse reactions.37
Such "Phase IIIb" trials are practical only if a serologic correlate of
efficacy is established during the "Phase IIIa" trials, as was done for the
licensure of combined DTP-Hib vaccines.38
Post-licensure
Once a vaccine has been shown to be efficacious, it would be unethical to
deliberately withhold it from certain populations in further studies to provide a
comparison group. Therefore in contrast to pre-licensure studies which have the relative
"simplicity" of experimental designs, most post-licensure studies are
observational and epidemiologic in nature. Issues of confounding and bias, which were
minimized by random allocation of vaccinated and unvaccinated persons in pre-licensure
studies, must now be either rigorously controlled for in-study design and analyses, or
taken into account during the interpretation of surveillance data.
Because of the limits in size, duration, and population heterogeneity of
preclinical trials, usually much remains to be learned about the characteristics of a
vaccine and its optimal use after licensure. Rarer adverse events, such as
vaccine-associated paralytic poliomyelitis39 or mumps vaccine-associated
aseptic meningtitis40, may not have been detected earlier. Certain batches of
vaccine may turn out to be unsafe or inefficacious, leading to improvements in
manufacturing and quality control.41 Some issues, such as duration of
vaccine-induced immunity may require decades to assess.42
Surveillance on several aspects of an immunization program are needed to
assure its optimal performance. This may include collection of data on vaccine
distribution, adequacy of the cold chain, adequacy of sterilization, the cost of the
vaccine, public attitudes towards the importance of immunizations, characteristics of
populations who have not been vaccinated, characteristics of remaining cases of disease,
characteristics of persons experiencing adverse reactions43, and even the
number of lawsuits filed against vaccine manufacturers.44 Special studies,
epidemiologic, laboratory, combination or others, may be needed to better understand and
solve potential problems identified by these immunization program surveillance/information
systems.
As immunizations change the epidemiology of vaccine-preventable diseases,
the immunization schedule may require fine tuning based on risk data from outbreak
investigations. This was the basis for changing the age for measles vaccination in the
United States from 9 months upon initial licensure to 12 months and then to 15 months.45
Modeling studies may also be used to better analyze strategy options46
Additional cost-effectiveness studies may be needed to garner continued program support.47
Serosurveys may be used to assess any major gaps in immunity that could result in future
outbreaks.48
A sophisticated surveillance system is also needed because of the dynamic
nature of the relationship between 1) disease incidence, 2) vaccine coverage, and 3)
vaccine adverse events as an immunization program progresses from pre-implementation to
final disease elimination/eradication (Figure 1). Information about at least these three
variables is needed by health authorities with responsibilities for weighing the costs,
risks, and benefits of an immunization program and recommendations for the use or
discontinuation of a vaccine. When the risk of complications from smallpox vaccine
exceeded that from smallpox itself in the United States, the Advisory Committee on
Immunization Practices (ACIP) recommended that smallpox vaccination be discontinued.49
To assure the correct decisions are made, the information system needed will have
to be tailored to each phase. At all times, both surveillance and special studies are
needed. However, the level of sophistication required of both types of information
generally increases with each phase.
Surveillance of Vaccine-Preventable Diseases
General Issues
Surveillance systems differ from special studies in that they are usually
designed to monitor trends, detect and describe problems, and to establish hypotheses to
be tested in more refined research designs.50 Surveillance systems are ongoing,
limited data are collected on each case, and data analysis is traditionally
straightforward. In contrast, special studies are usually designed to test specific
hypotheses, are usually time limited, data collection can be complex, and analyses are
often sophisticated.
All passive surveillance systems tend to generate incomplete data. Cases
of disease reported to surveillance systems are not random and may reflect a number of
biases. For example, reports of pertussis cases tend to include persons with the most
severe disease. About 40% of the pertussis cases reported to the Centers for Disease
Control and Prevention (CDC) were hospitalized51, compared with <10% in
community based studies.52 Despite underreporting and other potential
biases, surveillance data have been remarkably useful in serving the needs of public
health programs.53
Analysis of age-group specific measles surveillance data during the
1989-1990 measles outbreak pointed to the importance of unimmunized preschool children as
the main risk group54. A gradual increase in pertussis incidence after a long
historic decline may reflect waning immunity in adolescents and adults due to decreased
circulation of pertussis mostly from a successful vaccination program.55
Analysis of surveillance data may point out areas for special vaccination campaigns.
Examination of the U.S. measles surveillance data from 1980-1989 showed that measles was
endemic in only 0.5% of the nation's 3137 counties.56 Measles cases from
these counties were probably responsible for much of the measles transmission during these
years. These data added impetus to programs targeted at age-appropriate immunization of
children by age 2 in the U.S.57
Innovative analysis of surveillance data may provide insight into the
pathogenesis of vaccine-preventable diseases. The lack of expected increase in the
interepidemic period with increasing pertussis vaccination levels led Fine and Clarkson58
to hypothesize that pertussis vaccine was more effective in protecting against disease
than against infection. This hypothesis has since been supported by other studies.59
The rapid disappearance of diphtheria60 and Hib61 relative to
population vaccination levels suggest that, in addition to individual protection,
immunization may play a role in reducing carriage of pathogenic organisms. Comparison of
measles immunization rates, obtained via retrospective school surveys with measles attack
rates among census tracts in Milwaukee, Wisconsin, provided insight on the level of
herd immunity necessary to halt transmission.62
Top
of Page
Sources of Data
Most surveillance systems generally rely upon case reports by physicians,
other health care workers, or laboratories. This is particularly true for diseases like
measles and mumps with characteristic clinical symptoms and signs and for which few cases
are hospitalized and few attempts are made to confirm cases through the laboratory.
School-based surveillance, usually based on the school nurse, needs to identify reasons
for absenteeism. Frequently such reports are delayed because ill students may otherwise
escape detection until their return to school. This can impede control efforts if
vaccinations need to be started at the time of the first case.
For surveillance of diseases like invasive Hib disease,
laboratories and hospitals can be more useful because most cases of invasive illness are
both hospitalized and confirmed via the laboratory. Laboratory surveillance is
also important for pertussis, rubella, and hepatitis B because of the difficulties in
making the clinical diagnosis. Mortality records are used for evaluating health impact and
the characteristics of persons who die with a given disease. A special surveillance system
including deaths registered in 121 US cities each week is used to determine the existence
of an epidemic of influenza by comparing the reported proportion of total deaths due to
pneumonia and influenza with expected proportions based on nonepidemic years.63
In the United States, the Council of State and Territorial Epidemiologists
(CSTE), in collaboration with the CDC, develops the list of diseases recommended to be
reported by States to the CDC. Canada and most other countries have a similar process.64
Among the vaccine-preventable diseases, cases of diphtheria, tetanus, pertussis, polio,
Hib (invasive disease), measles, mumps, rubella, congenital rubella syndrome, hepatitis A
and hepatitis B are currently officially reportable via health departments of the states
and the District of Columbia on a weekly basis to the CDC. For selected diseases like
measles, pertussis, tetanus, polio, additional details on each case are gathered via a
supplementary surveillance form by county and state health staff. In addition, there are
special surveillance systems for Hib and hepatitis B disease. Varicella is a
notifiable disease in some states, and those data are shared on an annual basis with the
CDC.
Case Definitions
Case definitions vary with the goals of the surveillance system. For
example, prior to beginning a vaccination program or during its early phases, all
physician reports are usually accepted (i.e., the case definition is a physician
diagnosis). However, as disease incidence decreases and a greater degree of disease
control is achieved, individual cases are investigated by health department personnel, and
case definitions tend to become more precise. For example, the case definition for measles
can also require laboratory confirmation or epidemiologic linkage to another case meeting
the same clinical criteria. Clinical information from reported suspected cases of
poliomyelitis is now reviewed by a panel of three experts before being accepted as a case.65
These stricter definitions increase the predictive value positive of reported cases. The
predictive value positive would normally fall as disease incidence decreases unless
stricter definitions are used.
The current case definitions used by the CDC for notifiable
vaccine-preventable diseases have been published.66 Similar definitions have
been elaborated by Canada.64 Most of these definitions are based on
clinical and epidemiologic experience; some have been evaluated for sensitivity and
specificity during special investigations. For example, outbreak investigations in
Wisconsin, Delaware, and Missouri revealed that a case definition for pertussis of cough
for 14 or more days duration was 81% to 92% sensitive and 58% to 90% specific in the
outbreak setting. 67,68 The ideal sensitivity and specificity of case
definitions depends upon the outcomes desired from surveillance. For controlling
outbreaks, particularly during disease elimination and eradication, high sensitivity with
rapid reporting becomes important for early action. For studies, such as vaccine efficacy
evaluation, specificity assumes greater importance.20
Disease Registries, Sentinel and Universal Surveillance
Because of the expense and other difficulties of conducting large-scale
active surveillance on an entire population, some programs target sentinel sites for
special emphasis. For example, since 1982, the CDC has conducted intensive surveillance
and investigations of hepatitis in four sentinel counties.69 This
surveillance suggested that hepatitis B disease was underreported by 50%. In addition, the
comprehensive nature of the surveillance allowed greater confidence to be placed in the
data which showed decreasing prominence of persons citing homosexual behavior as a risk
factor and increasing prominence of intravenous drug abusers and persons engaging in
heterosexual activity.70
Well developed sentinel surveillance systems are used by some European
Governments to provide information on disease occurrence.71 The World
Health Organization's Expanded Programme on Immunization (EPI) has encouraged many
developing countries to adopt sentinel systems in which reports are accepted from selected
providers within a community, generally the large hospitals.72 Such sentinel
systems, while generally inexpensive, may give biased information depending upon how
representative the sites are of the general community. For example, hospital based systems
are more likely to report sicker children who tend to be younger and unvaccinated than
cases occurring in the community at large. Nevertheless, even these surveillance data are
useful for evaluating trends and estimating the initial impact of the vaccination program.73
Such systems may become less useful as wide vaccine use reduces disease incidence.
Special registries may be maintained for rare diseases of special
interest. The CDC maintained a registry which compiled data on women vaccinated with
rubella vaccines within 3 months of conception.74 The women were followed
prospectively to determine whether vaccination was associated with adverse pregnancy
outcomes. In 1989, the registry was discontinued when adequate data had been accumulated
to indicate that the risk of congenital rubella syndrome (CRS) following vaccination, if
any, was less than 1.2%. A similar registry has been started to follow pregnancy outcomes
after varicella vaccination. A Subacute Sclerosing Panencephalitis (SSPE) registry was
created to determine both whether vaccination against measles prevented the disease or
whether it could be caused by vaccination.75 Data thus far show that SSPE
has virtually disappeared from the United States.76
Evaluation
Guidelines for evaluation of public health surveillance systems have been
developed.77 Such evaluations consist of determining usefulness,
simplicity, flexibility, acceptability, sensitivity in detecting the true number of cases
or epidemics, predictive value positive of reported cases (i.e., the proportion of cases
reported that are true cases), representativeness of reported cases, timeliness of
reporting, and cost-effectiveness. With regard to immunization, major questions have
revolved around sensitivity and predictive value positive.
Estimates of underreporting are possible for diseases like measles which
are essentially universal childhood infections. Prior to the licensure of measles vaccines
in 1963, approximately 400,000 to 500,000 cases were reported annually at a time when
roughly 4,000,000 children were born each year. 27 Thus, the 400,000 to 500,000
cases reported represented approximately 10% of the total cases occurring in the United
States. Surveillance data were supplemented by special population-based studies which
corroborated the validity of the surveillance information. 28
Once the disease burden decreases due to vaccination, however, the total
remaining burden is difficult to estimate. Particular use has been made of the
Chandrasekar and Deming method of estimating the reporting efficiency for various
vaccine-preventable diseases in the United States. 78-81 This method requires
two independent surveillance systems detecting the same illness and measures the degree of
overlap to estimate the total burden. It is similar to capture-recapture systems used to
estimate animal populations. The efficiency of measles notification in England and Wales
has been estimated to be 40-60%, while that of pertussis is 5-25%.82
Efficiency of vaccine adverse events reporting can be evaluated if population-based
estimates based on prior studies are available.83 Predictive values
positive studies use gold standards such as laboratory confirmation to evaluate the
proportion of cases, given a particular case definition, that are laboratory confirmed.67
Serological Surveillance
Immunization programs aim to substitute vaccine-induced immunity for that
from disease. Neither history of disease or vaccination may be an accurate marker of true
immunity. Therefore, if a serologic correlate of protective immunity against a
vaccine-preventable disease exists, periodic serologic surveys are useful in 1) evaluating
the success of an immunization program and 2) identifying groups with low immunity that
might require changes in vaccination strategy.48
The United Kingdom switched from a selective to an universal rubella
immunization policy after results of routine antenatal testing showed an unacceptably high
rate of susceptibility.84 Hungary selected the age groups for a special
measles vaccination campaign based on serosurveys.85 Serosurveys in
recruits have been used to refine immunization policy in the military.86
Serosurveys in all countries with longstanding childhood vaccination programs against
diphtheria have shown a high proportion of adults to be susceptible.60 Not
surprisingly, adolescents and adults constitute a high proportion of diphtheria cases in
the current resurgence in Russia and Ukraine.87
As with all surveys, representativeness of the sample and participation
rate are critical to interpreting the results. More importantly, requirements for
obtaining, shipping, and laboratory assay of serologic specimens make serosurveys
relatively expensive. These factors plus the relative slow change in population immunity
profiles suggest that the frequency of serosurveys should be periodic [e.g. decennial
National Health and Nutrition Examination (NHANES) in the United States.88]
versus. annual.
Top
of Page
Vaccination Coverage
Because no vaccine is perfectly efficacious, vaccination levels are not
the same as immunity levels. Once rates of primary and secondary vaccine failure are known
from special studies, an estimate of immunity levels is possible in conjunction with
knowledge of the vaccination levels. In practice, because primary and secondary vaccine
failure rates are fairly low for most routinely recommended vaccines, vaccination levels
provide a reasonable measure of the progress of a vaccination program. Vaccination
coverage can be monitored via direct measurement of vaccination levels, or estimated
indirectly by several ways including 1) surveys, 2) reports of doses of vaccine
administered, and 3) reports of doses of vaccine distributed. As vaccine coverage reaches
high levels, indirect measurements may not provide the accuracy and precision needed to
improve the marginal coverage. Accurate ascertainment of vaccination history is also
critical to any epidemiologic study of vaccines as this represents the
"exposure".
Direct Measurement (Vaccination Registry, School Entry Census)
Since 1978, national immunization levels in the United States have been
assessed at school entry. Each State Health Department reports the results of their
assessment to the CDC where a national estimate is calculated. School enterer levels are
not measured by sample survey but represent a census of the immunization status of all
enterers. Each school must review the immunization status of each new enterer because of
laws requiring specified immunizations prior to admission to school. Data from each school
are usually compiled by school nurses or other school officials from immunization records
on file for each student. State immunization program personnel perform sample validation
surveys to confirm the school reports.89
The major advantage of this approach is that coverage levels are based on
records rather than parental recall. Since many parents do not have immunization records
of their children at home, persons doing telephone surveys, or even home visits would have
to list persons without records as unknown or rely on parental recall. Another advantage
of the school enterer assessment is that because it is a census, there is no potential
bias from sampling.
The major disadvantage is that immunization levels are measured several
years after vaccination should have been administered. A second problem relates to
validity of the records. Most states require physician confirmation of immunization
status. However, if physicians rely on parental recall rather than records to certify
immunization, falsely high immunization levels may be reported. Finally, assessment of
newly recommended infant vaccinations like Hib and Hepatitis B on a timely basis are not
possible from examining school enterer vaccination data.
In the United States, requirements for recording of vaccination
administration by providers has recently been legislated.90 These
requirements plus the increasing automation of health care practice has led several health
maintenance organizations (HMOs) to fully computerize their vaccination records.91
This permits easy, timely assessment of vaccination levels by physician, by clinic, as
well as for the health maintenance organization.92 Planning for expanded use of
such vaccination registries in the United States is underway.93 In
England and Wales, computerized preschool child registers combined with vaccination
histories have permitted more rapid, frequent, and accurate assessment of vaccine coverage
in almost all districts.94
Indirect Measurement - EPI 30 Cluster Survey
Surveys are commonly used to provide a more efficient estimate of
vaccination levels. Perhaps the best known is the 30 cluster two stage stratified random
survey initially developed for use during the smallpox eradication program.95
This method has since been used widely in World Health Organization's EPI as a
"gold standard" (with validity generally +10% of the actual levels) to
validate administrative estimates of vaccine coverage.96 It has also been
adapted to examine rates of neonatal tetanus deaths and polio lameness.97
Coverage Survey Analysis System (COSAS), a software to rapidly analyze the results of EPI
30 cluster surveys has been developed.98
The EPI survey has been criticized because the sampling frame is not based
on households but a convenience sample of the target population living in close proximity
to the selected starting point.99 Evaluation of the 30 cluster method, however,
has shown it to be generally accurate within the desired 10% of the true levels, though it
is particularly insensitive to pockets of unvaccinated persons.100 This can be
ameliorated by expanding the number of clusters to what the resources permit.101
The advantage of the 30 cluster method includes its relative ease of use with moderate
training. Its standard methodology permits aggregation of results from smaller
geographical areas.
The main disadvantage of the EPI survey is that the method requires a
sampling frame for the population of interest. Any census data available may be woefully
out-of-date, especially in rapidly growing urban areas in developing countries.102
Home vaccination records may be limited. Substantial logistical resources may also
be needed for the survey team to travel to remote locations selected for study. The EPI
survey can be particularly difficult to interpret if a substantial proportion of
respondents lack accurate vaccination records. This problem is likely to worsen as EPI
adds more vaccines requiring greater recall by parents. Techniques for improving the
accuracy and precision of the cluster survey method have been proposed. 99, 101
Top
of Page
Indirect Measurement - Other Surveys
The United States has tried a variety of approaches to estimating
vaccination levels among preschool children, none of which are entirely satisfactory. From
1959 to 1985, an annual survey of households to determine immunization levels for all key
age groups (United States Immunization Survey, USIS) was performed (published and
unpublished data. US Immunization Survey Reports, Division of Immunization, CDC,
Atlanta, Georgia, 1959-1985). Beginning in 1972, the data were collected principally by
telephone interview. Most of the answers were based on parental recall and the results
were generally substantially lower than the results of the school enterer assessments. In
1979, a question on whether parents were reading from records was added. Vaccination
levels based upon the approximately 1/3 of respondents with records more closely
approximated results from the school enterer assessments.103 Due to
concerns with the accuracy and cost of the USIS, it was abandoned after 1985.
The continuing need for timely data on national vaccination levels by 2
years of life, however, led to resumption of such surveys in 1991 via the National Health
Interview Survey (NHIS) using household interview of parents.104 The most
difficult problem for the NHIS was the lack of validity of parental history. In general,
parents tended to underestimate the number of doses of multidose vaccine their child
received and overestimate single dose vaccines (e.g., measles). When asked whether if
their child was up-to-date, however, parents tend to overestimate coverage.105
To compensate for these problems, beginning in 1992, a spontaneous response of "my
child is up-to-date" was accepted and children with unknown history were excluded.
These changes caused estimates to correlate better with other survey results. Beginning in
1994, parental responses are verified with providers. Preliminary data for the first two
quarters of 1994 suggest such verification will generally raise coverage by about 5%.106
In 1994, the National Immunization Survey was also initiated in the United
States. Using random digit dialing technology to locate eligible children, this survey
collects data quarterly to estimate immunization coverage in 19-35 month old children in
all 50 states and 28 large urban areas.107 Consent is obtained from the
interviewee to validate the vaccination history with the provider. Data are adjusted for
children from households without telephones based on NHIS data.108
Resources permitting, this survey will become the standard means for measuring coverage in
the future in the United States.
Other approaches to measuring preschool levels have included statewide
follow-up of a sample of children at two years of age who were selected from state birth
certificates.109 This technique also was abandoned in most states because
response rates were frequently low, often less than 50%, casting concerns on the validity
of the results. Recently, most states began measuring immunization levels retrospectively
using data obtained at school entry. Using date specific information, immunization
personnel calculate immunization levels for these enterers as of the date of their second
birthday.110
Guidelines and software for assessing vaccination levels of the 2-year-old
population in clinic settings has also recently been developed.111
Standards for definition of a 2-year-old, active vs. inactive files, age markers for
assessing vaccination levels, definition of "up-to-date" and complete
vaccination levels, and sampling of clinic charts may permit comparisons of clinics within
and between states. Such routine assessment and feedback of vaccination rates112
combined with reducing "missed opportunities" for vaccinations113
have been shown to be highly effective in raising and sustaining high vaccination rates.
Because the increasingly complicated childhood vaccination schedule114 will
increase the difficulty of accurately ascertaining vaccination history via interview,
computerized immunization registries are increasingly looked to as the answer for timely
and accurate assessment of vaccine coverage.93
Indirect Measurement - Administrative Estimate, Biologics
Surveillance, and Other Approaches
If the number of doses of vaccine administered and the number of children
in the target age group (e.g. number surviving infants) are known, an inexpensive
"administrative" estimate of vaccine coverage can be calculated. Again, if the
same method is used everywhere, then aggregation of data is possible. This is the method
used routinely by World Health Organization's EPI to estimate vaccine coverage.115
This method is most useful when the great majority of vaccinations are performed in
government-financed clinics (e.g., most developing countries) and accurate
denominator data on the population at risk is known. Commonly, however, these results are
higher than actual coverages as the census data used to estimate denominators tend to be
low.
Since 1962, the CDC has received data from vaccine manufacturers
concerning the number of doses of vaccines they distributed minus the number of doses
returned (published and unpublished data, US Biologics Surveillance, National Immunization
Program, CDC, Atlanta, Georgia, 1962-1996). Data on the "net doses" of vaccines
distributed have been helpful in tracking use of various types of measles vaccines.
Biologics data have also been useful in tracking DTP and DT vaccine following adverse
publicity about DTP vaccine which began in 1982 and triggered concerns that vaccine
coverage against pertussis would drop.116 The advantage of the biologics
surveillance system is that data become available relatively rapidly. If school entry data
were required, it would have taken about 5 years to obtain any information on infants born
and immunized following the onset of the adverse publicity.
In the United States, at least half of the childhood vaccines are
purchased by the government via annual negotiated contracts with the vaccine
manufacturers.117 A database recording purchases from this contract also
provides an alternative source of denominators. The major uses of these data have been in
monitoring the proportion of the population served by the public sector and in calculating
rates of adverse events reported following vaccination in the public sector.
Disease Surveillance
The ultimate purpose of immunization is to prevent disease and
complications of disease. Surveillance data on reported cases are critical to determine
whether the program is having an impact, to assess why disease is still occurring, to
evaluate whether new strategies are necessary, and to detect problem areas and populations
that require more intensive program input.
Disease surveillance systems initially need to be simple. Physician
diagnosis is usually the case definition, and reported information may include date of
onset or report, age, and place of residence. Such limited data have been useful to
demonstrate the marked impact of vaccination on disease incidence and for analyzing how
best to reduce remaining morbidity. For example, surveillance data were used to develop
policies to enhance rubella vaccination of postpubertal populations in the United States.81
Surveillance data were instrumental in the spread of regulations to
require vaccination for schoolchildren in the United States. Beginning in the mid 1970's,
surveillance data clearly showed that states without laws requiring vaccination at school
entry had 1.7 to 2.0 fold higher incidence rates of reported measles than states with
laws.118 This information was extremely useful in the universal adoption
of school enterer requirements by showing legislators that laws could lead to significant
impact. By the late 1970's, the epidemiology of measles had changed. Cases were more
prominent in junior high and high school students.119 These students were not
covered by the recently enacted school enterer laws since they had already been enrolled
when such regulations went into effect. This led to adoption of comprehensive laws
covering all students, kindergarten through 12th grade. Surveillance data showed such
states had lower incidence rates for measles than other states and lead to adoption of
comprehensive laws by most states.120
More recently, an analysis of reported mumps cases by age and by state
demonstrated that the marked increases in incidence were due to failure to vaccinate large
numbers of older children and adolescents rather than to vaccine failure.121
The highest incidence rates were in states without comprehensive school laws requiring
mumps immunization. If vaccine failure were the predominant concern, increased incidence
should have occurred in all states. Thus, evaluation of the role of vaccine failure was
possible without any data on vaccination status of cases.
Case Investigations
As programs mature and cases become more uncommon, surveillance tends to
move from simply the passive collection of limited data on cases to more sophisticated
individual case investigations by health department personnel. During these
investigations, staff generally collect relevant clinical and laboratory data as well as
information on disease complications, hospitalizations, vaccination status and other
desired information such as potential sources and contacts of the case. Health Department
personnel may assist in collecting critical laboratory specimens such as acute and
convalescent phase sera or providing transport media for bacterial and/or viral cultures.
In the United States, special case investigation forms were used historically for
congenital rubella syndrome, diphtheria, tetanus, pertussis, and hepatitis B. Detailed
information is collected on individual measles and polio cases. More recently, electronic
systems to compile this information directly have been developed. These data are used to
analyze cases in greater depth particularly with regard to health impact and problems with
vaccination.
A major question in control of vaccine-preventable diseases is whether a
given case represents a failure of implementation of the vaccine strategy (a preventable
case), or failure of the strategy (a nonpreventable case). For example, a preventable case
of measles is disease in someone who was eligible for vaccine but was unvaccinated.
In the past, such persons must have been born after 1956, be at least 16
months of age, be a US citizen, have no medical contraindications against measles
vaccination, have no religious or philosophical exemptions to vaccination under state law,
and have no evidence of measles immunity.122 Measles immunity was defined as
documented evidence of prior physician-diagnosed disease, receipt of live vaccine on or
after the first birthday, or laboratory evidence of immunity. Analyses of cases by
preventability status played a major role in new policy recommendations for more
aggressive revaccination efforts. In the mid-late 1980's, only a minority of cases were
preventable, and especially among school-age children, vaccine failure was the predominant
reason for nonpreventability.123 Analyses of large school-age outbreaks
in 1985 and 1986 (>100 cases) reported through the measles surveillance system
demonstrated as many as 69% of cases in such outbreaks were appropriately vaccinated with
one dose of measles-containing vaccine. Of the school-age cases in these outbreaks, a
median of 71% were vaccinated, ranging up to 90%. Case reports, many of them initiated by
physicians, played a crucial role in recommendations for a routine two dose schedule for
measles and for more aggressive outbreak revaccination efforts.124
Top
of Page
Outbreak Investigation
Disease outbreaks in a vaccinated population can raise doubts as to the
efficacy of the vaccine and the vaccination program.73 Such outbreaks may
result from accumulation of susceptible persons from 1) lack of vaccination, 2) primary
vaccine failures (persons vaccinated but not immunized), and/or 3) secondary vaccine
failures (persons successfully immunized initially but whose immunity subsequently wanes).125
Special studies to determine which of these factor(s) caused the outbreak are
needed to prevent recurrence and maintain public confidence in the vaccination program.
Special studies may be laboratory and/or epidemiologic in design. Testing
of residual vaccine used in outbreak areas may indicate poor potency, suggesting problems
in production126, formulation127, or refrigeration during shipping.128
Careful analysis of descriptive epidemiologic data from surveillance or outbreak
investigations may offer insights and hypotheses on possible causes worth testing via a
controlled epidemiologic study. Case-control studies were used in two measles outbreaks to
show that lack of provider verification of a school record of measles vaccination and
vaccination at <12 months of age were independent risk factors for measles disease. 129,
130 When the outbreak persisted despite a mass immunization campaign, a case-control
study showed that cases occurring after the campaign had all received vaccine from one jet
injector team, possibly due to poor administration technique.129 The same
studies showed that children who had been vaccinated in earlier years were no more likely
to be at risk for measles than recent vaccinees, suggesting waning immunity did not play a
role.
Unusual circumstances during outbreaks may permit the design of studies to
answer long-standing questions. A blood drive serendipitiously scheduled before a measles
outbreak on a college campus permitted correlation of preexposure antibody titers with
protection against classic and nonclassic measles.131 An explosive measles
outbreak in a high school where a single index case apparently exhausted all susceptibles
in the school during two days provided insight on the role of superspreader and airborne
modes in measles transmission. 130
Whenever studying outbreaks, however, it is important to place them in the
proper context. Most of the factors associated with vaccination failure are not uniformly
or randomly distributed in a population. Outbreaks, therefore, usually represent
exceptions rather than the rule. Modeling shows that investigation of outbreaks will tend
to underestimate the true vaccine efficacy in the population. The extent of
underestimation is dependent on epidemic size, vaccination coverage, clustering of
vaccination failures, community size, and contact rate.132
The high visibility of outbreaks may detract from the larger overall
accomplishment of the immunization program in decreasing disease incidence. A large
measles outbreak in Burundi in 198873 raised doubts about the effectiveness of
the measles vaccination program begun in 1982. Further analysis suggests that this was
most likely a "post-honeymoon period" outbreak predicted by mathematical models
of partially immunized population.133 Such periods are caused by the rapid
impact of early vaccination substantially decreasing susceptibility and limiting disease
transmission (the "honeymoon"). In the absence of disease, susceptibles
accumulate both because of failure to vaccinate and vaccine failure. Over time, these
susceptibles may be sufficient to fuel a megaoutbreak. However, even though this outbreak
may be large, it is more than compensated for by the long period of low disease incidence.
In Burundi, measles immunization had, in fact, successfully reduced measles morbidity and
mortality by 50% and increased the interepidemic period. 73 An understanding of
the dynamic interactions between susceptible and immune persons in a population and the
oscillations introduced by immunization programs are critical to immunization program
managers and policy makers. 32
Vaccine Efficacy and Vaccine Effectiveness Studies
No current vaccine is perfectly effective. The "intrinsic", non-preventable,
primary vaccine failure rates generally range from 2-50% for licensed vaccines even under
the ideal circumstances of clinical trials. Paradoxically, as the vaccine coverage in a
population increases, an increasing proportion of susceptibles and, hence, cases will have
a history of prior vaccination due to the intrinsic vaccine failure rate (table 2). While
the size of outbreaks should decrease with increasing vaccine coverage, the proportion of
cases with a vaccine history will increase. In the practical world of immunization
programs, vaccine failures may also occur due to preventable causes such as
problems in manufacturing,126 refrigeration,128 or administration
techniques.129
An epidemic in a highly vaccinated population along with the presence of
cases in many persons who had been vaccinated previously inevitably leads to public
concerns about vaccine efficacy. Post-licensure epidemiologic studies to assess vaccine
effectiveness may be needed to distinguish preventable from non-preventable causes of
vaccine failure and allay such concerns. 20 As discussed earlier, such
studies may also be needed because routine use of the vaccine after licensure may be in
populations or schedules that differ from pre-licensure trials. The range of efficacy with
the Hib polysaccharide vaccine depending on the population134 and of
influenza vaccine depending on the age group135 are some of the best examples.
Once a vaccine has been licensed, however, it would be unethical to
deliberately withhold an efficacious vaccine from a needy population. Therefore
observational or epidemiologic studies (with their greater attendant design challenges)
are used, instead of experimental study designs, to assess vaccine efficacy
post-licensure. Such studies are generally preferred to serological surveys for logistical
reasons, and also that for some vaccines, there is no accurate serologic correlate of
protection.
Top
of Page
Definitions
Immunization usually has the direct effect of inducing protective
immunity in the individual vaccinee. Occasionally, a vaccinated person may not
develop immunity due to primary failure. For most vaccine-preventable diseases,
immunization also has indirect effects of producing herd immunity for the population.21
Generally, the term vaccine efficacy has been applied to estimates of efficacy
derived from clinical trials where 1) vaccination occurs under optimal conditions and 2)
the limited sample size usually means that only direct protection is measurable. The term vaccine
effectiveness has been applied to observational epidemiologic studies of efficacy,
reflecting measurement of both direct and indirect effects of immunization in a population
under possibly suboptimal field conditions of vaccine storage, handling, and
administration.136 In practice, this distinction between vaccine efficacy and
effectiveness is frequently ignored; the term "vaccine efficacy" tends to be
used universally with some resultant confusion.137
Both vaccine efficacy and effectiveness
(VE) can be calculated using the
classic formula of Greenwood and Yule:19 1 - relative risk (equation 1), where
the Relative Risk is of developing disease. By convention, VE results are multiplied by
100 and expressed as a percent. Two different measures of the relative success of a
vaccine in protecting the recipient against disease are used in calculating VE.
Classically, when the data collected are in the form of total number of cases, the VE
calculation has been based on a comparison of the attack rates (or more accurately,
cumulative incidence or risk) among vaccinated and unvaccinated persons (equation 2).19,138
Alternatively, when the data available are in the form of number of cases during a certain
period of observation, person-time measures like incidence rates, hazard, or force of
infection are more appropriate (equation 3).139,140 Other measures used for VE
calculation include relative transmission probabilities141 and hazard ratio.142
Smith et al.140 have noted that how vaccines confer effective
protection may differ depending on a vaccine's mode of action. For example, a vaccine with
95% VE may 1) reduce the probability of infection by 95%, given equal exposure to
infection in all vaccinees, or 2) completely prevent infection in 95% of vaccinees and
confer no protection in the other 5%. Halloran et al.143 have further
elaborated the theoretical implications of the various models of vaccine action on both
vaccine efficacy and failure. Most clinical models assume that most vaccines either offer
full protection or no protection. The biologic basis for that assumption is clear. The
biologic basis for reducing the probability of infection is not clear. Dose-response
phenomena, in which the dose of pathogen a vaccinee is exposed to, might be a partial
explanation for the latter.
Screening for Vaccine Effectiveness
Before a formal epidemiologic study of vaccine effectiveness is
undertaken, it is useful to review whether the surveillance data permit a rapid
"screening" analysis. If the surveillance system routinely collects information
on the proportion of population vaccinated (PPV) and proportion of cases vaccinated
(PCV)
in the same population, and there is good confidence in the accuracy of these
data, then VE can be calculated via the following equation (4) derived algebraically (by
Orenstein et al. 144) from the classic VE equation of Greenwood and Yule.19
VE = 1 - Relative Risk
(1)
Attack Ratevaccinated
= 1- ________________ (2)
Attack Rateunvaccinated
Incidence Ratevaccinated
= 1 - __________________ (3)
Incidence Rateunvaccinated
(Proportion of cases vaccinated
1- Proportion of
population vaccinated)
= 1 - _________________________ X
______________________________ (4)
(1-proportion of cases vaccinated
Proportion of population
vaccinated)
Figure 2 depicts the relation between the two variables in equation 4 for
VE's ranging from 40 to 100%. This VE "nomogram" permits field health workers to
rapidly "screen" to see if the VE is within the expected range given the data on
PPV and PCV, which would suggest that the vaccine failures are non-preventable. A special
epidemiologic study for validation and identification of risk factors would be indicated
only if the screening suggests the VE is low. In the United Kingdom, linkage of cases,
their vaccination histories, and district vaccination coverages has permitted routine use
of this screening method for VE.145
In using the screening method, several cautions should be noted. First,
the method requires a dichotomous population of unvaccinated and fully vaccinated. Hence,
partially vaccinated persons need to be excluded from calculations of both PCV and
PPV.
Second, the method is most vulnerable to error under conditions of very low or very high
PPV and PCV. In these conditions, the VE curves tend to converge and small changes in PCV
or PPV can lead to major differences in VE.
Top
of Page
Study Design Considerations
Several epidemiologic study designs to evaluate VE are possible. 20
Cohort design is most appropriate when a discrete population at risk can be defined,
usually retrospectively (e.g. outbreaks in institutions and schools). If, however, the
outbreak is of longer duration or if vaccination status changes substantially during the
outbreak due to control efforts, then person-time or life table analysis is needed.139,140
Case-control137 studies maybe more efficient and perhaps the only practical
design for VE studies of diseases with lower case-to-infection ratio such as diphtheria146,
polio147, and tuberculosis.148 When the case attack rate is high,
the "rare" disease assumption for a cumulative incidence case-control study is
no longer valid. The case-cohort design149, essentially an incidence density
case-control study150, can be used instead. A sample of the population giving
rise to cases is taken irrespective of whether the sample includes some cases.151
The household secondary attack rate method aims to minimize bias
introduced by potential differences in risk of exposure among vaccinees and
nonvaccinees.
Data on attack rates among vaccinated and unvaccinated secondary contacts in many
households are aggregated into a cohort. VE for measles vaccine using this method is
similar to that from clinical trials.152 On the other hand, household secondary
attack rate studies may underestimate pertussis vaccine efficacy18,153 due to
intense exposure, selection of households with high likelihood of vaccine failure, and
retrospective case finding.154
Irrespective of the study design selected, an accurate VE calculation
requires 1) the accurate ascertainment of susceptibility, vaccination, and disease status
among the study population, and 2) similarity in other characteristics of the vaccinees
and nonvaccinees. While these criteria are relatively easily met in a prospective clinical
trial, they are not in an observational nonexperimental study (Figure 3), especially in
regards to comparability of vaccinees and nonvaccinees. The direction and the magnitude of
distortion from the true VE introduced due to errors in each of these variables in study
design have been extensively reviewed. 20,144,155 Among the major errors to
avoid are:
-
Assuming persons without a vaccination record are unvaccinated. Such
persons may have been vaccinated and lost their records or be truly unvaccinated. If the
former, this would falsely decrease the attack rateunvaccinated (ARU) and lead
to falsely low VE. Table 3 shows the calculated VE in a study in Burundi was only 51%
using this assumption.73 Some studies attempt to ascertain history of
vaccination among persons without records by interview. Such recall tends to be
unreliable, however, given the large number of injections and vaccinations administered.
The best strategy generally is to exclude the unknowns and restrict the analysis to
persons with record- documented vaccination and non-vaccination status.20 The VE
in Burundi increased to 59% when this was done (Table 4).
-
Using a nonspecific case definition is an example of the "bias
towards the null" in epidemiologic studies.156 As one would not expect a
vaccine to protect against a disease other than its target disease, specificity of
diagnosis is more critical to the accuracy of the vaccine efficacy estimate than
sensitivity.20 The endpoint "case definition" may be a laboratory
result, a clinical finding, or combination of both.59 For diseases with classic
symptoms like measles, clinical diagnosis by parent and/or doctor may be adequate in some
studies157, but not all.73 In Burundi, the VE further increased to
67% when a more specific case definition was used (Table 5). Assuming 100% sensitivity,
the magnitude of the error introduced by different levels of false-positive case
definitions is estimated by:
VEobserved ~ VEtrue(x/(x + y))
(5)
where x is the true incidence rate of the vaccine-preventable disease in
the population and y is the incidence of the condition misdiagnosed as the vaccine
preventable disease.155
-
Assuming vaccinees and nonvaccinees are otherwise similar, especially
in terms of susceptibility and risk of exposure to disease. In nonexperimental settings,
nonvaccinees generally differ from vaccinees in many ways, ranging from having
contraindications to vaccination, to personal choice, to others unknown to the
investigator. If the differences are related to both the exposure and outcome of interest,
the VE estimate may be biased by confounding. Potential confounding factors include, but
are not limited to, age, sex, race, socioeconomic status, attendance at school or
institution, and place of residence. Studies should collect data on, or match on,
suspected confounding variables to maximize comparability of vaccinees and nonvaccinees.20
Attempting to adjust for age further increases the VE estimate in Burundi to 73% (Table
6).
Top
of Page
Surveillance of Vaccine Safety
Vaccines are widely recommended or mandated, generally to otherwise
healthy persons. Because no vaccine is perfectly safe, immunization programs have an
obligation for careful monitoring of the safety of vaccines as well as their efficacy.158
As the incidence of vaccine-preventable diseases is reduced by increasing coverage with an
efficacious vaccine, vaccine adverse events, both causal and coincidental, become
increasingly prominent (Figure 1)159. Close monitoring and timely assessment of
suspected vaccine adverse events are critical to prevent loss of confidence, decreased
vaccine coverage, and return of epidemic disease. Epidemics of pertussis occurred in
several countries during the 1970's when concerns with the safety of pertussis vaccine
were widely publicized.160-162
Recommendations for use of vaccines represent a dynamic balancing of
benefits and risks. Vaccine safety monitoring is necessary to accurately weigh this
balance. When diseases are close to eradication, data on complications due to vaccine
relative to that of disease may lead to discontinuation of routine use of the vaccine, as
was done with smallpox vaccine.49 Few vaccine-preventable diseases are likely
to be eradicated in the near future, however. Most immunizations are, therefore, likely to
be needed indefinitely, with their attendant adverse events and potential for loss of
public confidence.
Common adverse reactions caused by vaccine can usually be detected in
prelicensure randomized, double-blind, placebo controlled trials. However, limits in
sample size, duration, and heterogeneity of pre-licensure trials also mean that rare,
delayed, or group-specific vaccine reactions are detectable only with wider use
post-licensure. The term "adverse events" temporally related to vaccine is
generally used post-licensure rather than "adverse reactions", since the word
reaction implies causation by the vaccine and causality is difficult to demonstrate in the
post-licensure setting.
Most commonly, postmarketing surveillance is done via passive reports.
Examples include the Vaccine Adverse Event Reporting System (VAERS)159 in the
United States and similar systems in other countries.163 Such passive adverse
events monitoring systems are most useful for identifying hypotheses for more detailed
investigation in special studies. Such hypotheses may consist of either previously
unreported vaccine adverse events (e.g. Guillain-Barre syndrome after "swine
flu" vaccine)164 or unusual increases in known events (e.g. cluster of
sterile abscesses associated with one manufacturer's product)165. Passive
systems are also used to monitor trends in reporting and can be used to evaluate some
hypotheses. For example, the predecessor system to VAERS requested information on personal
and family histories of seizures. Analysis showed that persons with such histories were
significantly more likely to have seizures following DTP than persons without such
histories, leading to development of precautions for vaccinating such individuals.43
Interpretation of passive systems is difficult due to 1) underreporting of
events and 2) biased reporting in favor of events occurring in closer temporal proximity
to vaccination. The greatest deficiency of passive surveillance, however, relates to their
general inability to determine whether a given reported event was actually caused by the
vaccination or simply coincidental to it. This is because most adverse events reported do
not have specific clinical (e.g. vaccine-associated polio) 39 or laboratory
characteristics (e.g. mumps vaccine meningitis)166 to differentiate them from
events that occur in the absence of vaccination. In such settings, epidemiologic
studies are necessary.
Passive reports like VAERS, however, generally contain only a biased
fourth of the information in a 2 x 2 table of vaccination exposure and adverse event
outcome needed for an epidemiologic assessment (i.e, they represent cell "a"
only: those vaccinated with adverse event) . They lack built-in control groups to allow
measurement of the incidence of the event in the absence of vaccination. Therefore, true
determination of causation usually requires special studies to gather information for all
four cells of a 2 x 2 table. The special studies can either be ad hoc165 or
increasingly, preorganized large-linked databases. Such databases take advantage of the
increasing automation of vaccination and medical records within medical care settings like
Health Maintenance Organizations91 and national health services167
to provide more scientifically rigorous estimates of vaccine risks.
To determine vaccine causation epidemiologically requires the
demonstration that either vaccinees are more likely to suffer the event than nonvaccinees
(cohort design) or persons with the event are more likely to have a history of recent
vaccination than persons without the event (case-control design). In highly vaccinated
populations, those persons remaining unvaccinated may confound studies of vaccine adverse
events168 Person-time "risk interval" analysis is then preferred.158
A risk interval for the adverse event is defined a priori based on biologic plausibility,
the incidence rates of the adverse event within and without the risk interval are then
compared. Adverse events with delayed or insidious onset cannot be assessed via this
method, however.
Recent reviews have identified major "gaps and limitations" in
both knowledge and research capacity on vaccine safety,169, 170 suggesting this
as one are requiring additional attention in maturing immunization programs.
Future issues
Recent explosive advances in biotechnology and biomedical knowledge offer
promises of development of candidate vaccines against many other infectious diseases.
Epidemiology will continue to play a critical role in their evaluation. Many other
difficult economic, ethical, and social issues need to be solved, however, before trials
for vaccines against HIV/AIDS can begin, let alone used routinely.171
Similarly, vaccines with a target population that is either limited in size or poor may
never be developed.7
The addition of new vaccines to the routine immunization schedule suggests
that combined vaccines requiring fewer injections and fewer visits are needed to maintain
continued high population immunity with minimal discomfort and highest compliance. Special
challenges, logistically and scientifically, exist in evaluating the safety and efficacy
of such combined vaccines.172 On the other hand, changes in health care
organization, especially its increasing centralization and automation173, offer
promising opportunities for epidemiologists to organize the studies necessary to continue
the miraculous conquering of diseases by immunizations.
Top
of Page
TABLE 1
Comparison of Maximum and Current Reported Morbidity
Vaccine-Preventable Diseases and Vaccine Adverse Events
United States, 1995
Disease |
Maximum cases (Year) |
1995* |
Percentage Change |
Diphtheria |
206,939 (1921) |
0 |
-99.99 |
Measles |
894,134 (1941) |
301 |
-99.97 |
Mumps |
152,209 (1968) |
840 |
-99.45 |
Pertussis |
265,269 (1934) |
4,315 |
-98.37 |
Polio (wild) |
21,269 (1952) |
0 |
-100.00 |
Rubella |
57,686 (1969) |
128 |
-99.78 |
Cong. Rubella Synd. |
20,000+ (1964-5) |
7 |
-99.96 |
Tetanus |
601 (1948) |
34 |
-97.82 |
Invasive Hib Disease |
20,000+ (1984) |
1,164 |
-94.18 |
Vaccine Adverse Events |
0+ |
10,594 |
* Final totals of reported cases to the CDC.
+ Estimated because no national reporting existed in the prevaccine era.
Top
of Page
FIGURE 1
TABLE 2
Relation between vaccine coverage and proportion of cases
vaccinated for a vaccine with < 100% vaccine efficacy
Total Population
|
100 |
100 |
100 |
100 |
Vaccine Efficacy (%) |
90 |
90 |
90 |
90 |
% population vaccinated |
20 |
60 |
90 |
100 |
No. vaccinated (total population x % population vaccinated) |
20 |
60 |
90 |
100 |
No. unvaccinated, i.e., susceptible (total population-no. vaccinated) |
80 |
40 |
10 |
0 |
No. protected by vaccine (no. vaccinated x vaccine efficacy) | 18 |
54 |
81 |
90 |
No. vaccinated but still susceptible (no vaccinated- no. protected by vaccine) |
2 |
6 |
9 |
10 |
Total no susceptible (no. unvaccinated + no. vaccinated but still susceptible) |
82 |
46 |
19 |
10 |
% susceptibles vaccinated (no. vaccinated but still susceptible/total no. susceptible). |
2.4 |
13 |
47 |
100 |
Top
of Page
FIGURE 2
Figure 2. Percentage of cases vaccinated
(PCV) per percentage of population vaccinated (PPV) for seven values of vaccine efficacy (VE).
FIGURE 3
Figure 3. Flow diagram of vaccine efficacy study. Prospective
clinical trial flows from left to right, while observational nonexperimental study during
an outbreak generally seeks to reconstruct the flow retrospectively going from right to
left.
Top
of Page
TABLE 3
Measles vaccine efficacy, Muyinga Sector, Burundi, 1988: all
children in census (measles cases as reported by mother; children without vaccination card
counted as unvaccinated)
|
Measles |
No measles |
Total |
Vaccinated |
115 |
893 |
1008 |
Unvaccinated |
207 |
685 |
892 |
Total |
322 |
1578 |
1900 |
Attack Rate Unvaccinated = 207/892 = 23%
Attack Rate Vaccinated = 115/1,008 = 11%
Vaccine Efficacy = (23% - 11%) / 23% = 1 - (11% / 23%) = 51%
TABLE 4
Measles vaccine efficacy, Muyinga sector, Burundi, 1988:
Unvaccinated children restricted to those with vaccination cards (on which there is no
record of measles vaccination)
|
Measles |
No measles |
Total |
Vaccinated |
115 |
893 |
1008 |
Unvaccinated |
122 |
316 |
438 |
Total |
237 |
1209 |
1446 |
Attack Rate Unvaccinated = 122/438 = 28%
Attack Rate Vaccinated = 115/1,008 = 11%
Vaccine Efficacy = (28% - 11%) / 28% = 1 - (11% / 28%) = 59%
Top
of Page
TABLE 5
Measles vaccine efficacy, Muyinga sector, Burundi, 1988: criteria
in table 4 plus measles patients restricted to those with symptoms meeting the case
definition of fever, rash, and cough, or runny nose, or red eyes
|
Measles |
No measles |
Total |
Vaccinated |
50 |
893 |
943 |
Unvaccinated |
60 |
316 |
376 |
Total |
110 |
1209 |
1319 |
Attack Rate Unvaccinated = 60/376 = 16%
Attack Rate Vaccinated = 50/943 = 5%
Vaccine efficacy = (16% - 5%) / 16% = 1 - (5% / 16%) = 67%
TABLE 6
Measles vaccine efficacy, Muyinga sector, Burundi, 1988: criteria
in table 4 plus table 5 plus analysis restricted to children > 9 moths of
age
|
Measles |
No measles |
Total |
Vaccinated |
41 |
701 |
742 |
Unvaccinated |
31 |
118 |
149 |
Total |
72 |
819 |
891 |
Attack Rate Unvaccinated = 31/149 = 21%
Attack Rate Vaccinated = 41/742 = 6%
Vaccine Efficacy = (21% - 6%) / 21% = 1 - (6% / 21%) = 73%
Top
of Page
References
1 World Bank. World Development Report 1993: Investing in
Health. New York: Oxford University Press 1993:72-107.
2 Acres SE, Varughese PV. Impact of vaccination on selected
diseases in Canada. Can Med Assoc J 1985;132:635-9.
3 Feery B. Impact of immunization on disease pattern in Australia.
Med J Aust 1981;2:172-6.
4 World Health Organization. Global Programme for Vaccines and
Immunization:Programme report 1994. Geneva:World Health Organization (WHO/GPV/95.1), 1995.
5 Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox
and its eradication. Geneva: World Health Organization, 1988.
6 Wright PF, Kim-Farley RJ, de Quadros CA, Robertson SE, Scott
RM,
Ward NA, Henderson RH. Strategies for global eradication of poliomyelitis by the year
2000. N Engl J Med 1991;325:1774-9.
7 Mitchell VS, Philipose NM, Sanford JP, eds. The childrenls
vaccine initiative: achieving the vision. Washington D.C.: National Academy Press, 1993.
8 Linehan DC, Goedegebuure PS, Eberlein
TJ. Vaccine therapy for
cancer. Annals of surgical Oncology. 1996;3:219-28
9 Illich I. Medical nemesis- the expropriation of health. New
York: Pantheon Books. 1976.
10 Begg N, Miller E. Role of epidemiology in vaccine policy.
Vaccine 1990;8:180-9.
11 Barre-Sinoussi F, Chermann
JC, Rey F, et al. Isolation of a
tlymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome
(AIDS). Science 1983;220:868-71.
12 Woodrow,GC. An overview of biotechnology as applied to vaccine
development. In: Woodrow GC, Levine MM, eds. New Generation Vaccines. New York: Marcel
Dekker 1990:31-41.
13 Levine MM. Vaccines and vaccination in the historical
perspective. In: Woodrow GC, Levine MM, eds. New Generation Vaccines. New York: Marcel
Dekker 1990:3-17.
14 Lee A. Animal models and vaccine development. Baillieres
Clinical Gastroenterology. 1995; 9:615-32.
15 Herrington DA. Initial clinical evaluation of new vaccine
candidates. In: Woodrow GC, Levine MM, eds. New Generation Vaccines. New York: Marcel
Dekker 1990:43-9.
16 Eskola J, Peltola H, Takala A, et al Efficacy of Haemophilus
influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N
Engl J Med 1987;317:717-22.
17 Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus
influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr
1992;121:355-62.
18 Mortimer EA, Kimura M, Cherry JD, et al. Protective efficacy of
the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids
following household exposure of Japanese children. Am J Dis Child 1990;144:899-904.
19 Greenwood M, Yule GU. The statistics of anti-typhoid and
anti-cholera inoculations. Proc R Soc Med 1915;8(part 2):113-94.
20 Orenstein WA, Bernier
RH, Hinman AR. Assessing vaccine efficacy
in the field. Further observations. Epidemiol Rev 1988; 10:212-241.
21 Fine
PEM. Herd immunity: history, theory, practice. Epidemiol
Rev 1993;15:265-302.
22 Centers for Disease Control. International Task Force for
Disease Eradication. Morb Mort Wkly Rept 1990;39:209-17.
23 Poore P. Vaccination strategies in developing countries.
Vaccine 1988;6:393-8.
24 Expanded Programme on Immunization. An integrated approach to
high coverage control of measles, elimination of neonatal tetanus, eradication of
poliomyelitis. Geneva: World Health Organization. WHO/EPI/GEN/93.21.
25 Foege WH, Millar JD, Lane
JM. Selective epidemiologic control
in smallpox eradication. Am J Epidemiol 1971;94:311-5.
26 Hull
HF, Ward NA, Hull BP, Milstein
JB, de Quadros C. Paralytic
poliomyelitis: seasoned strategies, disappearing disease. Lancet 1994;343:1331-7.
27 Langmuir AD. Medical importance of measles. Am J Dis Child
1962; 103:54-56.
28 Witte
JJ, Karchner AW, Case G, Herrmann
RL, Abrutyn E,
Kussanoff I, Neill JA. Epidemiology of rubella. Am J Dis Child 1969; 118:107-111.
29 Dudgeon JA. Selective immunization: protection of the
individual. Rev Infect Dis 1985;7:S185-90.
30 Bart KJ, Orenstein WA, Preblud SR, Hinman AR. Universal
immunization to interrupt rubella. Rev Infect Dis 1985;7:S177-84.
31 Gudnadottir M. Cost effectiveness of different strategies for
prevention of congenital rubella infection: a practical example from Iceland. Rev Infect
Dis 1985;7:S200-9.
32 Anderson
RM, May RM. Infectious diseases of humans: dynamics
and control. Oxford: Oxford University Press 1991:107.
33 Clemens J, Brenner R, Rao M. Et al Evaluating new vaccines for
developing countries. Efficacy or effectiveness? JAMA 1996;275:390-7.
34 Cochi SL, Broome CV, Hightower AW. Immunization of US children
with Haemophilus influenzae type b polysaccharide vaccine. A cost-effectiveness model of
strategy assessment. JAMA 1985253:521-529.
35 Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a
routine varicella vaccination program for U.S. children. JAMA 1994;271:375-81.
36 Ellis
RW, Douglas
RG. New vaccine techonologies. JAMA
1994;271:929-31.
37 Parkman PD, Hopps HE, Albrecht P, Meyer HM. Simultaneous
administration of vaccines. In: Halsey NA, de Quadros CA, eds. Recent advances in
immunization. Wash DC:PAHO Sci Pub No. 451:65-80.
38 Centers for Disease Control and Prevention. Recommendations for
use of Haemophilus b conjugate vaccines and a combined, diphtheria, tetanus,
pertussis, and Haemophilus b vaccine. Recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR 1993;42:6-8.
39 Henderson DA, Witte
JJ, Morris L, Langmuir AD. Paralytic
disease associated with oral polio vaccines. JAMA 1964;190:153-60.
40 McDonald
JC, Moore DL, Quennec P. Clinical and epidemiologic
features of mumps meningoencephalitis and possible vaccine-related disease. Pediatr Infect
Dis J. 1989;8:751-5.
41 Nathanson N, Langmuir AD. The Cutter Incident. American Journal
of Hygiene 1963;78:16-81.
42 Christenson B, Bottiger M. Long-term follow-up study of rubella
antibodies in naturally immune and vaccinated young adults. Vaccine 1994;12:41-5.
43 Stetler HC, Orenstein WA, Bart KJ, Brink
EW, Brennan JP, Hinman
AR. History of convulsions and use of pertussis vaccine. J Pediatr 1985;107:175-9.
44 Orenstein WA. DTP vaccine litigation, 1988. Am J Dis Child
1990;144:517.
45 Orenstein WA, Markowitz L, Preblud SR, Hinman AR, Tomasi A,
Bart KJ. Appropriate age for measles vaccination in the United States. Dev Biol Stand
1986; 65:13-21.
46 Massad E, Burattini MN, Azevedo Neto RS, Yang HM, Coutinho
FAB,
Zanetta DMT. A model-based design of a vaccination strategy against rubella in a
non-immunized community of Sao Paulo State, Brazil. Epidemiology and Infection 1994 (in
press).
47 Margolis HS, Coleman
PJ, Brown RE, et al. Prevention of
hepatitis B virus transmission by immunization: an economic analysis of current
recommendations. JAMA 1995; 274: 1201-8.
48 Evans AS. The need for serologic evaluation of immunization
programs. Am J Epidemiol 1980;122:725-31.
49 Centers for Disease Control. Public Health Service
recommendations on smallpox vaccination. MMWR 1971;20:339-45.
50 Thacker SB, Berkelman
RL. Public health surveillance in the
United States. Epidemiol Rev 1988; 10:164-190.
51 Farizo KM, Cochi SL, Zell ER, et al. Epidemiological features
of pertussis in the U.S., 1980-1989. Clin Infect Dis 1992;14:708-19.
52 Royal College of General Practitioners. Effect of a low
pertussis vaccination uptake on a large community. Br Med J 1981; 282:23-6~
53 Teutsch SM, Churchill RE, eds. Principles and practice of
public health surveillance. Oxford: Oxford University Press, 1994.
54 Gindler JS, Atkinson
WL, Markowitz LE. Update - the U.S.
measles epidemic, 1989-1990. Epidemiol Rev 1992;14:270-6.
55 Centers for Disease Control and Prevention. Resurgence of
pertussis-United States, 1993. MMWR 1993;42:952-3, 959-60.
56 Hersh BS, Markowitz LE, Maes
EF, et al. The geographic
distribution of measles in the US, 1980-1980. JAMA 1992;2667:1936-41.
57 The National Vaccine Advisory Committee. The measles epidemic:
the problems, barriers, and recommendations. JAMA 1991;266:1547-52.
58 Fine
PEM, Clarkson JA. The recurrence of whooping cough:
possible implications for assessment of vaccine efficacy. Lancet 1982;1:666-9.
59 Blackwelder WC, Storsaeter J, Olin P, Hallander HQ. Acellular
pertussis vaccines: efficacy and evaluation of clinical case definition. Am J Dis Child
1991;145:1285-9.
60 Chen
RT, Broome CV, Weinstein RA, et al. Diphtheria in the US,
1971-81. Am J Pub Hlth 1985;75:1393-7.
61 Adams
WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus
influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6.
62 Schlenker TL, Bain C, Baughman AL, Hadler SC. Measles herd
immunity: the association of attack rates with immunization rates in preschool children.
JAMA 1992;267:823-6.
63 Choi K, Thacker SB. An evaluation of influenza mortality
surveillance, 1962-1979. I. Time series forecasts of expected pneumonia and influenza
deaths. Am J Epidemiol 1981; 113:215-226.
64 Advisory Committee on Epidemiology. Canadian Communicable
Disease Surveillance System. Can Dis Wkly Rept 1991;17S3.
65 Strebel PM, Sutter
RW, Cochi SL, et al. Epidemiology of
poliomyelitis in the U.S. one decade after last reported case of indigenous wild
virus-associated disease. Clin Infect Dis 1992;14:568-79.
66 Centers for Disease Control. Case definitions for public health
surveillance. Morbid Mortal Wkly Rep 1990;39 (No. RR-13):[1-43].
67 Patriarca PA, Biellik RJ, Sanders G et al. Sensitivity and
specificity of clinical case definitions for pertussis. Am J Public Health 1988; 78:
833-836.
68 Strebel PM, Cochi SL, Farizo KM, et al. Pertussis in Missouri:
evaluation of nasopharyngeal culture, DFA testing, and clinical case definition in the
diagnosis of pertussis. Clin Infect Dis 1993;16:27685.
69 Alter
MJ, Mares A, Hadler SC, Maynard
JE. The effect of
underreporting on the apparent incidence and epidemiology of acute viral hepatitis. Am J
Epidemiol 1987; 125:133-139.
70 Centers for Disease Control. Changing patterns of groups at
high risk for hepatitis B in the United States. Morbid Mortal Wkly Rep 1988; 39:429-432,
437.
71 Valleron AJ, Bouvet E, Garnerin P, et al. A computer network
for the surveillance of communicable diseases:the French experiment. Am J Public Health
1986;76:1289-92.
72 Expanded Programme on Immunization. Evaluation and monitoring
of national immunization programmes. EPI/GEN/86/4 Rev 1, World Health Organization,
Geneva, Switzerland, 1986.
73 Chen
RT, Weierbach R, Bisoffi Z, et al. A 'Post-Honeymoon
Period' measles outbreak in Muyinga Sector, Burundi. Int J Epidemiol 1994;23:185-93.
74 Centers for Disease Control. Rubella vaccination during
pregnancy United States, 1971-1988. Morbid Mortal Wkly Rep 1989; 38:289-293.
75 Modlin JF, Jabbour JT, Witte
JJ, Halsey NA. Epidemiologic
studies of measles, measles vaccine, and subacute sclerosing panencephalitis. Pediatr
1977; 59:505-512.
76 Bloch AB, Orenstein WA, Stetler HC et al. Health impact of
measles vaccination in the United States. Pediatr 1985; 76:524-532.
77 Thacker SB, Parrish
RG, Trowbridge FL. Surveillance
Coordination Group. A method for evaluating systems of epidemiological surveillance. Wld
Hlt Statist Quart 1988; 41:11-18.
78 Sutter
RW, Cochi SL, Brink
EW, Sirotkin BI. Assessment of vital
statistics and surveillance data for monitoring tetanus mortality, United States,
1979-1984. Am J Epidemiol 1990; 131:132-142.
79 Sutter
RW, Cochi SL. Pertussis hospitalization and mortality in
the U.S., 1985-1988: evaluation of the completeness of national reporting. JAMA
1992;267:386-91.
80 Prevots DR, Sutter
RW, Strebel PM, Weibel RE, Cochi SL.
Completeness of reporting for paralytic poliomyelitis, U.S., 1980-1991. Arch Pediatr
Adoles Med 1994;148:479-85.
81 Cochi SL, Edmonds LE, Dyer K et al. Congenital rubella syndrome
in the United States, 1970-1985--on the verge of elimination. Am J Epidemiol 1989;
129:349-361.
82 Clarkson JA, Fine
PEM. The efficiency of measles and pertussis
notification in England and Wales. Int J Epidemiol 1985;14:153-68.
83 Rosenthal S, Chen RT. Reporting sensitivities of two passive
surveillance systems for vaccine adverse events. Am J Public Health 1995;85:1706-9.
84 Miller E. Rubella in the United Kingdom. Epidemiol Infect
1991;107:3142.
85 Agocs MM, Markowitz LE, Straub I, et al. The
1988-1989 measles epidemic in Hungary: assessment of vaccine failure. Int J
Epidemiol 1992; 21: 1007-113
86 Kelley PW, Petruccelli BP, Stehr-Green P, et al. The
susceptibility of young adult Americans to vaccine-preventable infections: a national
serosurvey of US Army Recruits. JAMA 1991; 266: 2724-9.
87 Hardy
IR, Dittman S, Sutter
RW. Current situtation and control
strategies for resurgence of diphtheria in newly independent states of the former Soviet
Union. Lancet. 1996;347:1739-44.
88 McQuillan GM, Gunter WE, Lannom L. Field issues for the plan
and operation of the laboratory components of the Third National Health and Nutrition
Examination Survey. J Nutr 1990;120S11:1446-50.
89 Eddins DL. Present systems that provide indicators of
immunization status of preschool children. In: Proceedings fo the 18th National
Immunization Conference. Atlanta, Georgia, May 16-19, 1983. Atlanta, GA: US
Department of Health and Human Services, Public Health Service, Centers for Disease
Control and Prevention, 1993: 83-4.
90 National Childhood Vaccine Injury Act: requirements for
permanent vaccination records and for reporting of selected events after vaccination.
MMWR Morb Mortal Wkly Rep 1988; 37:197-200.
91 Chen
RT, Glasser, J, Rhodes P, et al. The Vaccine Safety
Datalink Project: A New Tool for Improving Vaccine Safety Monitoring in the Unites States.
Pediatrics 1996 (in press).
92 Payne T, Kanvik S, Seward R, et al. Development and validation
of an immunization tracking system in a large health maintenance organization. Am J Prev
Med 1993;9:96-100.
93 National Vaccine Advisory Committee Subcommittee on Vaccination
Registries. Developing a national immuniation information system: registries, reminders,
and recall. Wash DC: National Vaccine Program Office, June 1, 1994.
94 Begg NT, Gill ON, White
JM: COVER (cover of vaccination
evaluated rapidly): description of the England and Wales scheme. Public Health 1989;
103:81-9.
95 Henderson
RH, Davis H, Eddins DL, Foege
WH. Assessment of
vaccination coverge, vaccination scar rates, and smallpox scarring in five areas of West
Africa. Bull WHO 1973;48:183-94.
96 Henderson
RH, Sundaresan T. Cluster sampling to assess
immunization coverage: a review of experience with simplified sampling method. Bull WHO
1982;60:253-60.
97 Cutts FT. The use of the WHO cluster survey for evaluating the
impact of the expanded programme on immunization on target disease incidence. J Trop Med
Hyg 1988;91:231-9.
98 EPICENTRE. Coverage Surveys and Computerized Analysis
(COSAS),
software for EPI 30 cluster coverage surveys. User Manual. Geneva:World Health
Organization, 1991.
99 Brogan D, Flagg
EW, Deming M, Waldman R. Increasing the
accuracy of the Expanded Programme on Immunization's cluster survey design. Ann Epidemiol
1994;4:302-11.
100 Lemeshow S, Tserkovnyi AL, Tulloch
JL, et al. A computer
simulation of the EPI survey strategy. Int J Epidemiol lY~;14:473-81.
101 Turner AG, Magnani RJ, Shuaib M. A not quite as quick but much
cleaner alternative to the Expanded Programme on Immunization (EPI) cluster survey design.
Int J Epidemiol 1996;25:198-203~
102 Ferrinho P, Valli A, Groeneveld T, et al. The effects of
cluster sampling in an African urban setting. Cent Afr J Med 1992;38:324-30.
103 Eddins DL. Indicators of Immunization Status. 17th
Immunization Conference Proceedings, Atlanta, Georgia, May 18-19, 1982, P47-55.
104 Centers for Disease Control and Prevention. Vaccination
coverage of 2year-old children - United States, 1992-1993. MMWR 1994;43:282-3.
105 Goldstein
KP, Kviz
FJ, Daum RS. Accuracy of immunization
histories provided by adults accompanying preschool children to a pediatric emergency
room. JAMA 1993;270:2190-4.
106 Centers for Disease Control and Prevention. Vaccination
coverage levels among children aged 19-35 months United States, April-June 1994. MMWR
1995;44:396-8.
107 Centers for Disease Control and Prevention. The State and
National Vaccination Coverage Levels Among Children Aged 19-35 Months - United States,
April-December 1994. MMWR 1995;44:613, 619-23.
108 Massey JT, Botman SL. Weighting adjustments for random digit
dialed surveys. In: Broves RM, Blemer PP, Lyberg LE, et al. Telephone survey methodology.
New York: John Wiley & Sons, Inc. 1988:143-60.
109 Hutcheson
RH, Barid
SJ. An inexpensive methodology for
immunization surveys. Pub Hlth Rep 1974;89:315-9.
110 Centers for Disease Control and Prevention. Retrospective
assessment of vaccination coverage among school-aged children - selected US cities, 1991.
MMWR 1992;41:103-7.
111 National Immunization Program. Clinic Assessment Software
Application (CASA). Atlanta, GA: CDC, 1994.
112 Centers for Disease Control and Prevention. Recommendations of
the Advisory Committee on Immunization Practices: programmatic strategies to increase
vaccination rates - assessment and feedback of provider-basedvaccination coveraqe
information. MMWR 1996;45:219-20.
113 Szilagyi PG, Rodewald LE. Missed opportunities for
immunizations: a review of the evidence. J Public Health Management Practice 1996;2:1825.
114 Recommended childhood immunization schedule-United States,
January-June 1996. MMWR Morb Mortal Wkly Rep 1996; 44: 940-3.
115 Expanded Programme on Immunization. Training for
Mid-Level Managers Increasing Immunization Coverage. Geneva:World Health Organization.
WHO/EPI/MLM/91.2.
116 Centers for Disease Control. Biologics Surveillance Teport No.
93 (1987 to 1990). Atlanta, GA:Centers for Disease Control, 1991.
117 Centers for Disease Control and Prevention. Vaccines for
Children Program, 1994. MMWR 1994;43:705.
118 Orenstein WA, Halsey NA, Hayden GF et al. Current status of
measles in the United States 1973-1977. J Infect Dis 1978; 137:847-853.
119 Centers for Disease Control: Measles Surveillance Report No.
11 1977-1981. Issued September 1982.
120 Robbins
RB, Brandling Bennett AD, Hinman AR. Low measles
incidence: Association with enforcement of school immunization laws. Am J Public Health
1981; 91:270-274.
121 Cochi SC, Preblud SR, Orenstein WA. Perspectives on the
relative resurgence of mumps in the United States. Am J Dis Child 1988; 142:499-507.
122 Centers for Disease Control. Classification of measles cases
and categorization of measles elimination programs. Morbid Mortal Wkly Rep 1982;
31:707-711.
123 Markowitz LE, Preblud SR, Orenstein WA, Rovira
EZ, Adams NC,
Hawkins CE, Hinman AR. Patterns of transmission in measles outbreaks in the United States
1985-1986. N Engl J Med 1989; 320:75-81.
124 Centers for Disease Control. Recommendations of the
Immunization Practices Advisory Committee (ACIP). Measles Prevention. Morbid Mortal Wkly
Rep 1989; 38:No. S-9:1-18.
125 Hinman AR, Orenstein WA, Mortimer EA. When, where, and how do
immunizations fail? Ann Epidemiol 1992;2:805-12.
126 Hlady WG, Bennet JV, Samadi AR, et al. Neonatal tetanus in
rural Bangladesh: risk factors and toxoid efficacy. Am J Pub Hlth 1992;82:1365-9.
127 Patriarca PA, Laender F, Palmeira G, et al. Randomized trial
of an alternative formulation of polio vaccine in Brazil. Lancet 1988;1:42933.
128 Hayden
GF. Measles vaccine failure: a survey of causes and
means of prevention. Clin Pediatr 1979jl8:155-67.
129 Wassilak SGF, Orenstein WA, Strickland PL, et al. Continuing
measles transmission in students despite a school-based outbreak control program. Am J
Epidemiol 1985;122:208-17.
130 Chen
RT, Goldbaum GM, Wassilak
SGF, Markowitz LE, Orenstein
WA. An explosive point-source measles outbreak in a highly immunized population: modes of
transmission and risk factors for disease. Am J Epidemiol 1989j129:173-182.
131 Chen
RT, Markowitz LE, Albrecht P, et al. Measles antibody:
reevaluation of protective titers. J Infect Dis 1990; 162:1036-1042.
132 Fine
PEM, Zell ER. Outbreaks in highly vaccinated populations:
implications for studies of vaccine performance. Am J Epidemiol 1994;139:77-90.
133 McLean AR, Anderson RM. Measles in developing countries, Part
II. the predicted impact of mass vaccination. Infect Imm 1988;100:419-42.
134 Ward J, Lieberman
JM, Cochi S. Haemophilus influenzae
vaccines. In: Plotkin SA, Mortimer EA, eds. Vaccines. Philadelphiao Saunders,
1994:337-386.
135 Kilbourne EA. Inactivated influenza vaccines. In: Plotkin SA,
Mortimer EA, eds. Vaccines. Philadelphia:WB Saunders; 1994:565-82.
136 Halloran ME, Haber M, Longini IM, Struchiner CJ.. Direct and
indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 1991:133:323-31.
137 Comstock
GW. Evaluating vaccination effectiveness and vaccine
efficacy by means of case-control studies. Epidemiol Rev 1994;16:77-89.
138 Francis T, Korns
RF, Voights RB, et al. An evaluation of the
1954 poliomyelitis vaccine trials. Am J Pub Health 1955;45:1-63.
139 Francis DP, Hadler SC, Thompson SE, et al. The prevention of
hepatitis B with vaccine: Report of the Centers for Disease Control multi-center efficacy
trial among homosexual men. Ann Intern Med 1982;97:362-6.
140 Smith PG, Rodrigues LC, Fine
PEM. Assessment of the protective
efficacy of vaccines among common diseases using case-control and cohort studies. Intl J
Epidemiol 1984;13:87-93.
141 Haber M, Longini IM, Halloran ME. Measures of the effects of
vaccination in a randomly mixing population. Intl J Epidemiol 1991;20:300-10.
142 Brunet RC, Struchiner CM, Halloran ME. On the distribution of
vaccine protection under heterogeneous response. Math Biosci 1993;116:111-25.
143 Halloran ME, Haber M, Longini IM. Interpretation and
estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 1992;136:328-43.
144 Orenstein WA, Bernier
RH, Dondero TJ, et al. Field evaluation
of vaccine efficacy. Bull WHO 1985;63:1055-68.
145 Farrington CP. Estimation of vaccine effectiveness using the
screening method. Intl J Epidemiol 1993;22:742-6.
146 Hardy
IR, Monisov A, Filatov N, et al. Major epidemic of
diphtheria, Russia, 1990-93. 43rd Annual Epidemic Intelligence Service Conference.
Atlanta: CDC:1994.
147 Deming MS, Jaiteh KO, Otten MW, et al. Epidemic poliomyelitis
in the Gambia following the control of poliomyelitis as an endemic disease. II:clinical
efficacy of trivalent oral polio vaccine. Am J Epidemiol 1992;135:393-408.
148 Smith PG. Retrospective assessment of the effectiveness of BCG
vaccination against tuberculosis using the case-control method. Tubercle 1982;62:23-35.
149 Prentice
RL. A case-cohort design for epidemiologic cohort
studies and disease prevention trials. Biometrika 1986;73:1-12.
150 Hogue
CJR, Gaylor
DW, Schulz KF. Estimators of relative risk
for casecontrol studies. Am J Epidemiol 1983;118:396-407.
151 Cutts FT, Smith PG, Colombo S, et al. Field evaluation of
measles vaccine efficacy in Mozambique. Am J Epidemiol 1990;131:349-55.
152 King GE, Markowitz LE, Patriarca PA, et al. Clinical efficacy
of measles vaccine during the 1990 measles epidemic. Pediat Infect Dis J 1991;10:883-7.
153 Onorato IM, Wassilak
SG, Meade B. Efficacy of whole-cell
pertussis vaccine in preschool children in the United States. JAMA 1992;267:2745
154 Fine
PEM, Clarkson JA, Miller E. The efficacy of pertussis
vaccinesunder condition of household exposure. Intl J Epidemiol 1988;17-635-42.
155 Fine
PEM, Clarkson JA. Reflections on the efficacy of
pertussis vaccines. Rev Infect Dis 1987;9:866-83.
156 Rothman KJ. Modern epidemiology.
Boston:Little, Brown and
Company, 1986.
157 Measles Vaccination Committee. Vaccination against measles: a
clinical trial of live measles vaccine give alone andd live vaccine preceded by killed
vaccine. Br Med J 1966;1:441-6.
158 Chen RT. Special methodological issues in pharmacoepidemiology
studies of vaccine safety. In:Strom BL, ed. Pharmacoepidemiology. Sussex:John
Wiley;1994:581-94
159 Chen
RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse
Event Reporting System (VAERS). Vaccine 1994;12:542-50.
160 Kimura M, Kuno-Sakai H. Developments in pertussis immunisation
ln Japan. Lancet 1990;336:30-2.
161 Miller DL, Alderslade R, Ross
EM. Whooping Cough and Whooping
Cough Vaccine: the Risks and Benefits Debate. Epidemiol. Rev. 1982;4:1-24.
162 Krantz I, Taranger J, Trollfors B. Estimating incidence of
whooping cough over time: a cross-sectional recall study of four Swedish birth cohorts.
Int J Epidemiol 1989;18:959-63.
163 Duclos P, Pless R, Koch J, et al. Adverse events
temporally associated with immunizing agents. Can Fam Physician 1993; 39:1907-13.
164 Schonberger LB, Bregman DJ,
Sullivan-Bolyai JZ, et al.
Guillain-Barre Syndrome following vaccination in the national influenza immunization
program, United States, 1976-1977. Am J Epidemiol 1979;110:105-23.
165 Bernier RH, Frank JA Jr, Nolan TF Jr. Abscesses complicating DTP
vaccination. Am J Dis Child 1981; 135:826-8.
166 Forsey T, Mawn JA, Yates
PJ, Bently ML, Minor PD.
Differentiation of vaccine and wild mumps viruses using the polymerase chain reaction and
dideoxinucleotide. J Gen Virol 1990;71:987-90
167 Farrington P, Pugh S, Colville A, et al. A new method for
active surveillance of adverse events from diphtheria/tetanus/pertussis and
measles/mumps/rubella vaccines. Lancet 1995; 345: 567-9
168 Fine PEM, Chen RT. Confounding in studies of adverse
reactions to vaccines. Am J Epidemiol 1992; 136: 121-35.
169 Howson CP, Howe CJ, Fineberg
HV, eds. Adverse effects of
pertussis and rubella vaccines. Washington DC: National Academy Press, 1991.
170 Stratton KR, Howe CJ, Johnston
RB, eds. Adverse events
associated with childhood vaccines. Washington DC:National Academy Press, 1994.
171 Committee on Life Sciences and Health. The human
immunodeficiency virus vaccine challenge: issues in development and international trials.
Washington, DC: Executive Branch, Office of Science and Technology Policy, 1993.
172 Willaims
JC, Goldenthal KL, Burns D, et al., eds.
Combined vaccines and simultaneous administration: current issues and perspective. New
York, NY: New York Academy of Sciences, 1995.
173 Strom BL, Canson
JL. Use of automated databases for
pharmacoepidemiology research. Epidemiol Rev 1990; 12: 87-107.
|